Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.82 |
| ▸ | CNR1 | P21554 | 10/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921357 | 0.92 | MAPT (0.82) | MAPTCNR1KDRRAB9ACNR2 | |
| SCHEMBL4118606 | 0.91 | MAPT (0.76) | MAPTCNR1KDRNPC1RAB9A | |
| SCHEMBL4922831 | 0.90 | MAPT (0.79) | MAPTCNR1KDRNPC1RAB9A | |
| SCHEMBL4912509 | 0.90 | MAPT (1.00) | MAPTCNR1CNR2 | |
| Hydrochloric Acid SCHEMBL4915559 | 0.89 | MAPT (0.98) | MAPTCNR1CNR2 | |
| SCHEMBL4915532 | 0.84 | MAPT (0.70) | MAPTCNR1NPC1RAB9ADNMT3B | |
| SCHEMBL4119185 | 0.84 | MAPT (0.70) | MAPTCNR1KDRCNR2FGFR3 | |
| SCHEMBL4922785 | 0.78 | MAPT (0.61) | MAPTCNR1 | |
| SCHEMBL8312358 | 0.77 | PLK1 (0.59) | MAPTKDRFGFR3PLK1DNMT3B | |
| SCHEMBL20557632 | 0.77 | CNR1 (1.00) | MAPTCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804785-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006049941-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | WO | claimed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | MAPT 1654/4885CNR1 1/4885KDR 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.